Search
VA-MENGOC-BC®
go.drugbank.com/drugs/DB15800ExperimentalAs of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C.
1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline
go.drugbank.com/drugs/DB08555ExperimentalThis compound belongs to the isoquinolines and derivatives. … This medication is known to target mitogen-activated protein kinase 10.
Esflurbiprofen
go.drugbank.com/drugs/DB16159InvestigationalEsflurbiprofen is under investigation in clinical trial NCT03434197 (Safety and Efficacy of SFPP in Knee Osteoarthritis).
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseRumex crispus top
go.drugbank.com/drugs/DB14167ApprovedWithdrawnRumex crispus top allergenic extract is used in allergenic testing.
Synonyms: Rumex crispus topIsoliquiritigenin
go.drugbank.com/drugs/DB03285ExperimentalIsoliquiritigenin is a precursor to several flavonones in many plants.
Eprodisate
go.drugbank.com/drugs/DB06405InvestigationalEprodisate slows the decline of renal function in AA amyloidosis.
9-(4-hydroxybutyl)-N2-phenylguanine
go.drugbank.com/drugs/DB02495ExperimentalThis compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.
N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid
go.drugbank.com/drugs/DB03458ExperimentalThis compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.
Mizolastine
go.drugbank.com/drugs/DB12523ApprovedMizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).
Categories: Antihistamines for Systemic UseBRG01
go.drugbank.com/drugs/DB18173InvestigationalBRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]